Search results
Results from the WOW.Com Content Network
The best-selling statin is atorvastatin, also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history. [12] The manufacturer Pfizer reported sales of US$12.4 billion in 2008. [13] Patient compliance with statin usage is problematic despite robust evidence of the benefits. [14] [15]
Atorvastatin, sold under the brand name Lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. [6] For the prevention of cardiovascular disease, statins are a first-line treatment. [ 6 ]
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia).
Statins are a type of medication that can help lower a person’s “bad” cholesterol, helping reduce their risk for cardiovascular disease.
A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors in bladder cancer, a new study finds.
An ingredient in "A.P.C." tablet; withdrawn because of risk of cancer and kidney disease [42] Germany Denmark, UK, US, others Reason: nephropathy. [3] Phenformin and Buformin: 1977 France, Germany US Severe lactic acidosis [3] Phenolphthalein: 1997 US Possible carcinogen. [43] Phenoxypropazine: 1966 UK Hepatotoxicity, drug intereaction. [3 ...
Drugs with other primary uses, that have known uricosuric properties, include losartan, [1] atorvastatin, and fenofibrate.Although these drugs may have significant uricosuric action, their other significant pharmacological actions in off-label use as a uricosuric requires careful assessment of the patient to achieve the most benefit and least risk.
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]